Cognition Therapeutics' Drug Shows Promise in Treating Dementia with Lewy Bodies
TL;DR
Cognition Therapeutics Inc. (NASDAQ: CGTX) announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat dementia with Lewy bodies.
The phase 2 SHIMMER study enrolled 130 adults who were randomized to receive either placebo or one of two oral once-daily doses of CT1812 (100 mg or 300 mg) for six months. Participants were assessed using the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research (CDR) Battery, and other measures.
The study met its primary endpoint of safety and tolerability, with data showing that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive, and movement measures compared to the placebo. This could potentially make the world a better place by providing hope to those suffering from DLB.
The SHINE study results showed a 95% slowing of cognitive decline in individuals with mild-to-moderate Alzheimer’s disease, demonstrating the broad neurologic and neuroprotective activity of CT1812.
Found this article helpful?
Share it with your network and spread the knowledge!
Cognition Therapeutics Inc. (NASDAQ: CGTX) has reported encouraging topline results from its Phase 2 SHIMMER study of CT1812, an experimental oral drug aimed at treating dementia with Lewy bodies (DLB). The clinical-stage company's announcement marks a significant step forward in addressing a form of dementia that affects approximately 1.4 million people in the United States and is currently without a cure.
The SHIMMER study, which enrolled 130 adults, demonstrated that CT1812 produced strong therapeutic responses across multiple measures in DLB patients. Notably, the drug showed an 82% slowing in the total neuropsychiatric inventory, with particular improvements in anxiety, hallucinations, and delusions. The study also reported a marked reduction in caregiver distress, suggesting potential improvements in patients' daily lives.
Cognition Therapeutics' Chief Medical Officer, Dr. Anthony Caggiano, expressed that the results exceeded expectations and support the broad potential of CT1812 across neurodegenerative disorders. The company plans to present detailed data at the International Lewy Body Dementia Conference in January 2025.
The positive outcome of the SHIMMER study builds on the company's previous success with CT1812 in a Phase 2 trial for Alzheimer's disease, where it demonstrated a 95% slowing of cognitive decline in patients with a key biomarker. These combined results strengthen the case for CT1812's potential efficacy in treating multiple neurodegenerative conditions.
The development of CT1812 is particularly significant given the lack of existing treatments for DLB, which is characterized by rapid symptom onset and can quickly lead to declines in thinking, reasoning, and independent movement. As the costliest form of dementia, an effective treatment could have substantial implications for patients, caregivers, and healthcare systems.
With these promising results, Cognition Therapeutics is poised to move forward with late-stage clinical trials, potentially bringing a once-daily pill to market that could treat both DLB and Alzheimer's disease. The company's progress represents a beacon of hope for millions affected by these devastating neurodegenerative conditions and could potentially reshape the landscape of dementia treatment.
Curated from News Direct
